baiosphere’s Post

Our CEO spoke about new biotech advances centered around autonomous therapeutic systems (no. 2 in the article). Don't get it? We'll have an informative video about this very significant tech soon. Meanwhile, think of this as the Cliff Notes.

📣 The #BioTechX conference has concluded, and now it's time for everyone to head home. 🤝 We want to extend our heartfelt gratitude to all those we had the pleasure of connecting with during the event. ⭐️ The future ahead is undeniably promising. In light of this, we’d like to take a moment to shine a spotlight on a few remarkable booths and startups that truly stood out: 🧑💻TileDB - Manage, analyse, and collaborate on single-cell data at scale 💊DeepLife - Identify druggable targets and biomarkers with digital twin of cells 🩻 Raidium - Tackle the complexity of precision medicine with Radiology augmented GPT 📊 knowing01 - Decipher multi-omics data at scale to make informed decisions 🚀 Prometheus Life Technologies - Grow high quality tissue organoids under microgravity conditions From all of us at Zifo, stay curious 👋

Our second 3RsC TDB Thursday will focus on the benefits of these Translational Digital Biomarkers for the 3Rs. TDB are digital technologies that collect physiological and behavioural data from research animals. These technologies can: 1. Refine animal's lives while they are being used for research. 2. Reduce the number of animals necessary for each experiment. 3. Collect data continuously, longitudonally and non-invasively. 4. Increase translatability from preclinical to human data. 5. Have the potential to be scalable to hundreds/thousands on animals. Has this peaked your interest? To learn more about the different TDB technologies that exist and talk directly with companies that provide them, you can visit our TDB Tech Hub: https://lnkd.in/e6F4GQv References Baran et al. 2022. Emerging Role of Translational Digital Biomarkers Within Home Cage Monitoring Technologies in Preclinical Drug Discovery and Development. Frontiers, 15. https://lnkd.in/gZ_RsEV7

🧬 Heading home from a riveting week in Munich at #BioEurope2023. The meeting kicked-off with an opening plenary session on #AI and #healthcare, moderated by Sofinnova's Simon Turner, Partner with the firm's newly-minted Digital Medicine Fund, recently closed at $200 million. Simon was joined on stage by Thomas Clozel, Owkin and Najat Khan, PhD, Johnson & Johnson, exploring AI's expansive role in making healthcare more patient-centric. The discussions touched on AI's impact beyond #drugdiscovery, the outlook for #precisionmedicine, and the efficiency and cost savings new information technologies can bring. Thomas gave a shoutout to Sofinnova for being one of the few bilingual players in the space – able to speak two “languages” – #biotech and #infotech. 🙏 Graziano Seghezzi, Managing Partner at Sofinnova, also took to the stage to offer a distinct perspective on the art of #dealmaking as part of a panel moderated by Anton Gueth from EVOLUTION Life Science Partners and Evonne Sepsis from ESC Advisors. He was joined by pharma representatives Guillaume Vignon from Novartis and John McDonald from Novo Nordisk. Graziano described what it is like to embody the dual role of buyer and seller, a dichotomy that makes the job of a venture capitalist unique and complex, especially in the current market landscape. Finally, our portfolio company CEO Dr. Franz MJ Pfister, MD, MBA of deepc spoke about AI and Big Data with BioM’s Ralf Huss. They were joined by Director General Bavarian Ministry, Ulrike Wolf and EBD Group’s Claire Macht. Thanks to EBD Group for having us and looking forward to seeing many of you next year. #BIOEurope2023 #DigitalMedicine #VentureCapital #Biotech #Investment

Owkin , the first end-to-end AI biotech unicorn offering world-class AI-driven precision drug discovery, development and diagnostics, has announced its expansion into the DACH region (Germany, Austria and Switzerland). After partnering with nine of the region's leading centers, including Charité - Universitätsmedizin Berlin, Centre Hospitalier Universitaire Vaudois (CHUV), University Hospital Basel, Technical University of Munich (TUM), University Hospital Erlangen, University Hospital Leipzig, Insel Gruppe in Bern, University Hospital Mannheim-Heidelberg and Medical University of Vienna. These collaborations represent an unprecedented representation of patient populations, covering 24% of all outpatient cases and 15% of all patients in the DACH region. Guillaume Bézie, Director of Partnerships in Western Europe: “The Western European network, which includes France, the Benelux countries and the DACH region, forms the largest pool of centers for Owkin. Our collaboration with leading academic institutions has irreplaceable value for our expansion strategy. By involving patients from different backgrounds for different diseases, we can use our AI to better respond to the unique needs of each individual. Together with our partners, we are fully dedicated to accelerating the use of secondary benefits of #multimodal patient data to provide the right treatment to each patient.” Philipp Mann, Venkat Sethuraman, Yedidia Levy-Zauberman, Thomas Bonnotte, Ph.D., MS, Pierre-Antoine Bannier, Philip Conti-Permanne To share your startup story write us on - [email protected] #Owkin #biotech #AI #Unicorn #development #news #startup

🔍 Insights from Matthias Kromayer at BayOConnect in Munich! 🔍 This week, Matthias Kromayer held a presentation at BayOConnect by BioM Biotech Cluster Development GmbH. Under the theme "Reflections on AI from an Agnostic VC Investor," Matthias shared MIG Capital’s reflections on the potential impact of #AI within the #biopharma value chain. Key points included: 🚀 The Fight: Understanding the role of AI in revolutionizing clinical trials. 📊 Analysis: Breaking down AI’s potential in enhancing trial design, site selection, real-time monitoring, and patient experiences. 🔍 Conclusion: Assessing AI’s transformative power across the biopharma value chain, from early development to market approval. #BayOConnect2024 was fun – see you next year! 💡 Bayerisches Staatsministerium für Wirtschaft, Landesentwicklung und Energie | Roche Deutschland

'A New National Purpose: Leading the Biotech Revolution is a joint report by Tony Blair and William Hague.' Congratulations to the team of authors who have put forward such an ambitious vision for the United Kingdom. The challenge as always will be whether a future government will be bold enough/have the bandwidth to enact the recommendations in this report. Some key points: Focus is key: 'This report is not intended to be a comprehensive life-sciences strategy or an industry analysis that addresses every area of biotech. Instead, it highlights critical areas of focus for Britain: 1. how we can seize the global opportunity that biotech represents in the AI era; 2. how data can be harnessed better to drive research and help create AI doctors that can complement GPs’ expertise by acting as personalised health advisors; 3. what we should do to become home to the next generation of superstar companies; and 4. how to keep ourselves and the rest of the world safe from global biothreats.' Reimagining the shape of the state to deliver focused objectives: 'Some recommendations are technical solutions to the policy and organisational problems biotech faces in the UK, but they feed into the broader theme of how strategic application of innovation and the right infrastructure can power a reimagined state in which people lead better, longer, safer lives. The common thread throughout this report is a question: building on Britain’s existing strengths, what does “reimagining the state” look like for biotechnology and the opportunity it presents?' What's the answer ? ' new institutions and endeavours' including: The UK Laboratory of Biodesign, The MediMind laboratory network to work towards personalised AI doctors in partnership with industry and the National Health Service (NHS) A new NHS Data Trust (NHSDT) to capitalise on the opportunities of health data. Owned and controlled by the NHS in collaboration with trusted external partners, the NHSDT would treat NHS data as a competitive asset whose value can be realised for the benefit of the public. A cognitive challenge for a future Government and it's departmental structures: 'Beyond proposing the institutions that will futureproof our infrastructure, Leading the Biotech Revolution poses new strategic directions for government – an essential mindset shift towards a practical focus on the priorities for British biotech. Securing our place at the frontier of global research, building high-value biomedical data for discovery, making the UK a place where high-potential companies can grow and become giants of the global economy – these are the essentials.' https://lnkd.in/dUmdgcs7

🚀 On the Cusp of Bio-Europe 2023 🚀 As the buzz for Bio-Europe 2023 builds, I am eager to step into a space where health innovation isn't just discussed, it's catalyzed. It's an unparalleled chance to meet those shaping our future. Hurdle stands at this frontier, pushing the boundaries of epigenetics and precision medicine. We've harnessed epigenetic biomarker discovery, integrating multi-omics to unearth novel biomarkers—turning data into insights with our state-of-the-art infrastructure. It's not merely about data collection; it's about reimagining diagnostics. Our platform is a testament to the power of virtualization and decentralization, redefining participation in clinical trials and bringing us closer to the patients we serve. The horizon of companion diagnostics is expanding, and at Hurdle, we're laying down the tracks for targeted therapies to travel further, faster. With each novel biomarker, we refine endpoint definitions, streamline clinical trials, and enhance real-world evidence generation. Our integrated omics approaches are not just pinpointing therapeutic targets; they're lighting the way from lab to clinic at unprecedented speeds. Our specialty lab services ensure that no stone is left unturned, from early discovery to advanced clinical trials. At Bio-Europe, I look forward to forging connections that will accelerate these advancements. We're not just part of the conversation—we're driving it. See you in Munich, where together, we'll shape the healthcare of tomorrow. #BioEurope2023 #Innovation #HealthTech #Epigenetics #PrecisionMedicine #HurdleInnovation